(Boursier.com) — Phaxiam Therapeutics announces a very broad spectrum of activity of its anti-S phages. aureus (PP1493 and PP1815) against clinical bacterial strains. A retrospective analysis was performed on 105 clinical strains of Staphylococcus aureus, tested using the Phaxiam phagogram in clinical trials, salvage therapies and Compassionate Access Authorizations (CAAs). The results demonstrated that 98% of these pathogenic S. aureus strains were sensitive to at least one of the two anti-S phages. aureus of PHAXIAM (PP1493 and PP1815).
The Phagogram is an in vitro diagnostic (IVD) test designed to measure the sensitivity of bacterial strains present in patients to Phaxiam Therapeutics phages. It is also the first IVD test dedicated to the evaluation of phage activity which has CE marking.
©2023 Boursier.com